Pharma's Preferred Patent Reforms May Be Too Expensive
This article was originally published in The Pink Sheet Daily
Executive Summary
Sen. Schumer supports exempting Rx industry from inter partes review, but tells BIO conference that legislators must find $1.2 billion to enact it; calls for industry code of conduct on pricing.